Nabla Bio Secures $26M Series A Financing and Collaborations with AstraZeneca, Bristol Myers Squibb and Takeda for Generative Protein Design
Summary
We are unlocking new opportunities to build highly selective drugs against validated, but hard-to-drug targets with a degree of structural precision not previously possible, said Nabla Co-Founder and CEO Surge Biswas. We are excited to welcome Radical Ventures as our newest investor and to announce collaborations with three of the worlds largest pharmaceutical companies to help us bring our work closer to patients. On the other hand, multipass membrane proteins are far more challenging to drug, due to their membrane-integrated nature, limited extracellular availability, conformational dynamics, and structural similarity across targets. These collaborations also offer valuable insights into disease biology and platform development while offsetting a significant portion of R&D expense, enabling Nabla to grow quickly and sustainably. Their groundbreaking work on multipass membrane protein targets offers to revolutionize antibody therapeutics and has won them major commercial partnerships with several of the worlds largest pharmaceutical companies.